Influenza vaccination in children primed with MF59^®-adjuvanted or non-adjuvanted seasonal influenza vaccine

References

• Pan American Health Organization Immunization in the Americas. 2013 Summary. PAHO. Washington DC 2013, 1–12.
   Google Scholar
• Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59(RR-8):1–62; PMID:20689501
   PubMedGoogle Scholar
• Ropero-Alvarez AM, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C, Andrus JK. Expansion of seasonal influenza vaccination in the Americas. BMC Pub Health 2009;9:361; http://dx.doi.org/10.1186/1471-2458-9-361
   PubMed Web of Science ®Google Scholar
• Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infectious Dis 2012;54(10):1427–36; http://dx.doi.org/10.1093/cid/cis211
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2010–2011 Influenza Season Summery. http://www.cdc.gov/flu/weekly/weeklyarchives2010–2011/10–11summary.html. Accessed 22 April 2014.
   Google Scholar
• Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, Finelli L. Influenza-associated pediatric deaths in the United States, 2004–2012. Pediatrics 2013;132(5):796–804; PMID:24167165; http://dx.doi.org/10.1542/peds.2013-1493
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012;30(5):886–92; PMID:22155144; http://dx.doi.org/10.1016/j.vaccine.2011.11.104
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 2012;31(1):49–57; PMID:23142300; http://dx.doi.org/10.1016/j.vaccine.2012.10.084
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12(1):36–44; PMID:22032844; http://dx.doi.org/10.1016/S1473-3099(11)70295-X
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356(7):685–96; PMID:17301299; http://dx.doi.org/10.1056/NEJMoa065368
   PubMed Web of Science ®Google Scholar
• Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011;365(15):1406–16; PMID:21995388; http://dx.doi.org/10.1056/NEJMoa1010331
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011;30(12):1081–5; PMID:21983214; http://dx.doi.org/10.1097/INF.0b013e3182367662
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, Icardi G. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010;28(25):4123–9; PMID:20433807; http://dx.doi.org/10.1016/j.vaccine.2010.04.030
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Exp Rev Vacc 2011;10(4):447–62; http://dx.doi.org/10.1586/erv.11.23
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R. Homologous and heterologous antibody responses to a one-year booster dose of an MF59((R)) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 2012;8(7):921–8; PMID:22777094; http://dx.doi.org/10.4161/hv.20248
   PubMed Web of Science ®Google Scholar
• Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 2010;28(45):7331–6; PMID:20813217; http://dx.doi.org/10.1016/j.vaccine.2010.08.075
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009;27(49):6959–65; PMID:19751689; http://dx.doi.org/10.1016/j.vaccine.2009.08.101
   PubMed Web of Science ®Google Scholar
• Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, Himanen SL, Hublin C, Julkunen I, Olsén P, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PloS One 2012;7(3):e33536; PMID:22470453; http://dx.doi.org/10.1371/journal.pone.0033536
   PubMed Web of Science ®Google Scholar
• Melon K, Partinen M, Tynell J, Sillanpää M, Himanen S-L, Saarenpää-Heikkilä O, Hublin C, Olsen P, Ilonen J, Nohynek H, et al. No serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy After Pandemrix Vaccination Campaign in Finland. Plos One 2013; 8(8):e68402; PMID:23950869; http://dx.doi.org/10.1371/journal.pone.0068402
   PubMedGoogle Scholar
• Lyytikäinen O, Kuusi M, Toikkanen M, Virtanen M, Rönkkö E, Strengell M, et al. The surveillance results of the second wave of 2009 pandemic influenza A (H1N1) in Finland, November 2010-April 2011. Lääkärilehti 2011; 40:2925–2930 (English Summary)
   Google Scholar
• Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Pediatrics 2006;118(3):e570–8; PMID:16950948; http://dx.doi.org/10.1542/peds.2006-0198
   PubMedGoogle Scholar
• Skowronski DM, Hamelin ME, Janjua NZ, De Serres G, Gardy JL, Rheaume C, Bouhy X, Boivin G. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PloS One 2012;7(6):e38929; PMID:22745690; http://dx.doi.org/10.1371/journal.pone.0038929
   PubMedGoogle Scholar
• Skowronski DM, Hottes TS, De Serres G, Ward BJ, Janjua NZ, Sabaiduc S, Chan T, Petric M. Influenza Beta/Victoria antigen induces strong recall of Beta/Yamagata but lower Beta/Victoria response in children primed with two doses of Beta/Yamagata. Pediatr Infect Dis J 2011;30(10):833–9; PMID:21857263; http://dx.doi.org/10.1097/INF.0b013e31822db4dc
   PubMed Web of Science ®Google Scholar
• Center of Disease Control and Prevention (CDC): Key facts about seasonal flu vaccine. http://www.cdc.gov/flu/protect/keyfacts.htm
   Google Scholar
• Durando P, Iudici R, Alicino C, Alberti M, de Florentis D, Ansaldi F, Icardi G. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vacc 2011; 7 Suppl: 29–40; http://dx.doi.org/10.4161/hv.7.0.14560
   PubMed Web of Science ®Google Scholar
• Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Exp Ref Anti-Infect Ther. 2011;9(6):669–83; PMID:21692672
   PubMedGoogle Scholar
• Katz J, Kancock K, Veguilla V, Zhong W, Lu XH, Sun H, et al. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR 2009; 58(19): 521–4; PMID:19478718
   PubMedGoogle Scholar
• Montomoli E, Capecchi B, Hoschler K. Correlates of protection against influenza. In: Influenza vaccines for the future, 2nd edition. Rappuoli R, del Giudice G (eds). 2011. Springer, Basel
   Google Scholar
• Banzhoff A, Stoddard J. Effective influenza vaccines for children. A critical unmet medical need and a public health priority. Hum Vaccin Immunother. 2012; 8(3): 398–402; PMID:22327501; http://dx.doi.org/10.4161/hv.18561
   PubMedGoogle Scholar
• Ng S, Fang VJ, Ip DK, Chan KH, Leung GM, Peiris JS, Cowling BJ. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis. 2013;208(8):1320–4; PMID:23908481; http://dx.doi.org/10.1093/infdis/jit372
   PubMed Web of Science ®Google Scholar
• Bodewes R, Fraaij PL, Geelhoed-Mieras MM, van Baalen CA, Tiddens HA, van Rossum AM van der Klis FR, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Annual vaccination against influenza virus hampers development of virus-specific CD8+ T cell immunity in children. J Virol 2011; 85(22): 11995–20000; PMID:21880755; http://dx.doi.org/10.1128/JVI.05213-11
   PubMed Web of Science ®Google Scholar
• Bodewes R, Kreijtz RH, Rimmelzwaan GF. Yearly influenza vaccinations: a double-edged sword? Lancet Infect Dis 2009; 9(12):784–8; PMID:19879807; http://dx.doi.org/10.1016/S1473-3099(09)70263-4
   PubMed Web of Science ®Google Scholar
• Bodewes R, Kreijtz K, Hillaire ML, Geelhoed-Mieras MM, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J Gen Virol 2010; 91 (7): 1743–53; PMID:20335492; http://dx.doi.org/10.1099/vir.0.020784-0
   PubMed Web of Science ®Google Scholar
• Sridhar S, Begom S, Bermingham A, Hoscler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013; 19(10):1305–12; PMID:24056771; http://dx.doi.org/10.1038/nm.3350
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 2008;82(11):1598–606; http://dx.doi.org/10.1128/JVI.02694-07
   Web of Science ®Google Scholar
• van de Sandt CE, Kreijtz JH, de Mutsert G, Geelhoed-Mieras MM, Hillaire ML, Vogelzang van Trierum SE, Osterhaus AD, Fouchier RA, Rimmelzwaan GF. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol 2014; 88(3):1684–93; PMID:24257602; http://dx.doi.org/10.1128/JVI.02843-13
   PubMed Web of Science ®Google Scholar
• Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, Farrar JJ, Smith GL, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008; 118(10):3478–90; PMID:18802496
   PubMed Web of Science ®Google Scholar
• Quiñones-Parra S, Grant E, Loh L, Nguyen TH, Campbell KA, Tong SY, Miller A, Doherty PC, Vijaykrishna D, Rossjohn J, et al. Pre-existing CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc Natl Acad Sci USA 2014;111(3):1049–54; http://dx.doi.org/10.1073/pnas.1322229111
   PubMed Web of Science ®Google Scholar
• Coulter A, Wong TY, Drane D, Bates J, Macfarlan R, Cox J. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines. Vaccine 1998; 16(11–12): 1243–53; PMID:9682385; http://dx.doi.org/10.1016/S0264-410X(98)80125-4
   PubMed Web of Science ®Google Scholar
• Zedda L, Forleo-Neto E, Vertruyen A, Raes M, Marchant A, Jansen W, Clouting H, Arora A, Beatty ME, Galli G, et al. Dissecting the Immune Response to MF59-adjuvanted and Nonadjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age. Pediatr Infect Dis J 2015; 34(1):73–8; PMID:25037034; http://dx.doi.org/10.1097/INF.0000000000000465
   PubMed Web of Science ®Google Scholar
• FDA Food and Drug Administration. Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. May 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf. Accessed 22 April 2014
   Google Scholar
• The Committee for Proprietary Medicinal Products (CHMP). Note for guidance on hamonisation of requirements for influenza vaccines. CHMP/ BWP/214/96. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf Accessed 22 April 2014
   Google Scholar